Palvella Therapeutics【PVLA】銘柄情報

Palvella Therapeutics Inc (PVLA) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

107.73

( -0.87% )

買値

106.95

売値

108.57

出来高

211,661

107.005 日の範囲 120.00

20.20 52 週間の範囲 151.18

時価総額

1.545B

前日終値

108.67

始値

110.80

時刻

107.6273

最終取引時間

01:50:38

財務取引量

US$ 23,165,752

VWAP

109.4474

平均取引量 (3 か月)

US$ 245,766

発行済株式数

14,342,844

配当利回り

PER

-25.94

1 株当たり利益 (EPS)

-4.19

歳入

純利益

-49.3M

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase ... Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

palvellatx.com

本社

Wayne, United States

設立

Palvella Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker PVLA. The last closing price for Palvella Therapeutics was US$108.67. Over the last year, Palvella Therapeutics shares have traded in a share price range of US$ 20.20 to US$ 151.18.

Palvella Therapeutics currently has 14,342,844 shares in issue. The market capitalisation of Palvella Therapeutics is US$1.55 billion. Palvella Therapeutics has a price to earnings ratio (PE ratio) of -25.94.

Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

Palvella remains on track to submit an NDA in the second half of 2026 Microcystic lymphatic malformations are...

Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”...

Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043

Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis...

Form 4 - Statement of changes in beneficial ownership of securities

Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards

WAYNE, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq:...

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malforma

In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as “Much Improved” (+2) or...

Form 8-K - Current report

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology

100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-11.27	-9.47058823529	119	120	104.37	319169	111.97946518	CS
4	-14.02	-11.5154004107	121.75	128.39	101.29	223723	114.45760947	CS
12	-16.35	-13.1769825919	124.08	138.64	101.29	238981	120.0330459	CS
26	6.75	6.68449197861	100.98	151.18	72.225	280583	110.2017619	CS
52	81.8	315.464712688	25.93	151.18	20.2	229412	90.48887186	CS
156	94.09	689.809384164	13.64	151.18	11.1	177063	82.46952222	CS
260	94.09	689.809384164	13.64	151.18	11.1	177063	82.46952222	CS